OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press54710.17650/1818-8346-2022-17-2-151-153RESOLUTIONРЕЗОЛЮЦИЯExperts Council Resolution on topical issues in the treatment of patients with idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) and thrombopoietin receptor agonist (avatrombopag)Резолюция Совета экспертов, посвященного актуальным вопросам терапии пациентов с идиопатической тромбоцитопенической пурпурой (первичной иммунной тромбоцитопенией) и агонисту тромбопоэтиновых рецепторов (аватромбопагу)140420221721511531404202214042022https://oncohematology.abvpress.ru/ongm/article/view/547

.

12 ноября 2021 г. состоялся Совет экспертов, на котором были обсуждены современные возможности лечения пациентов с идиопатической тромбоцитопенической пурпурой, или первичной иммунной тромбоцитопенией (ИТП), а также данные международных клинических исследований эффективности и безопасности препарата аватромбопаг.

French Society for Haematology (2017). Available at: http://www.esculape.com/ald/ALD2-Purpura-thrombopeniqueimmunologique.pdf.Spanish Society for Haematology (2011). Available at: https://www.sehh.es/en/documents/consensus/1743-directricesde-diagnostico-tratamiento-yseguimiento-de-la-pti-documento-deconsenso.NHS SWL Guidelines (2019). Available at: https://selondonccg.nhs.uk/wp-content/uploads/dlm_uploads/2021/09/ImmuneThrombocytopenia-ITP-adult-PathwayFINAL-July-2020.pdf.Provan D., Arnold D.M., Bussel J.B. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780–817. DOI:10.1182/bloodadvances.2019000812.Neunert C., Terrell D.R., Arnold D.M. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3(23):3829–66. DOI:10.1182/bloodadvances.2019001380.González-Porras J.R., Godeau B., Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol 2019;10:2040620719837906. DOI:10.1177/2040620719837906.Çekdemir D., Güvenç S., Özdemirkıran F. et al. Multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: a real-life experience. Turk J Haematol 2019;36(4):230–7. DOI:10.4274/tjh.galenos.2019.2018.0307.Mingot-Castellano M.E., Caparrós I.S., Fernández F. et al. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia. Blood Coagul Fibrinolysis 2018;29(4):374–80. DOI:10.1097/MBC.0000000000000726.Instructions for medical use of the drug Revolade, ЛСР-010032/09-221121. Available at: https://grls.rosminzdrav.ru/Default.aspx (accessed on 13.02.2022). (In Russ.).Инструкция по медицинскому применению препарата Револейд, ЛСР-010032/09-221121. Доступно по: https://grls.rosminzdrav.ru/Default.aspx (по состоянию на 13.02.2022).Instructions for medical use of the drug Nplate, ЛП-№(000352)-(РГ-RU). Available at: https://grls.rosminzdrav.ru/ Default.aspx (accessed on 13.02.2022). (In Russ.).Инструкция по медицинскому применению препарата Энплейт, ЛП-№(000352)-(РГ-RU). Доступно по: https://grls.rosminzdrav.ru/Default.aspx (по состоянию на 13.02.2022).Birocchi S., Podda G.M., Manzoni M. et al. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets 2021;32(2):216–26. DOI:10.1080/09537104.2020.1745168.European Medicines Agency. Doptelet (avatrombopag). Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet.Kuter D.J., Allen L.F. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol 2018;183(3):466–78. DOI:10.1111/bjh.15574.Bussel J.B., Kuter D.J., Aledort L.M. et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 2014;123(25):3887–94. DOI:10.1182/blood-2013-07-514398.Jurczak W., Chojnowski K., Mayer J. et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol 2018;183(3):479–90. DOI:10.1111/bjh.15573.Al-Samkari H., Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets 2022;33(2):257–64. DOI:10.1080/09537104.2021.1881952.Cheloff A.Z., Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 2019;10:313–21. DOI:10.2147/JBM.S191790.Nagalla S., Tian W., Vredenburg M., Allen L.F. Platelet response to avatrombopag in patients with chronic immune thrombocytopenia: additional analyses from a phase 3 study and its extension. Blood 2019;134(Suppl_1):1071. DOI:10.1182/blood-2019-130963.Al-Samkari H., Jiang D., Gernsheimer T. et al. Switching from eltrombopag or romiplostim to avatrombopag in immune thrombocytopenia: a multicenter study of U.S. ITP Referral Centers [abstract]. Res Pract Thromb Haemost 2021;5(Suppl 2).